News
The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.
7h
Zacks.com on MSNAstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...
Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.
6d
SurvivorNet on MSNNew Hope for Patients With Advanced Lung Cancer: Datroway, A New FDA ApprovalA new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
4d
Pharmaceutical Technology on MSNModella AI and AstraZeneca link for cancer clinical developmentModella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.
Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.
Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results